汲取眼部黑色素瘤协作研究经验,提高中国葡萄膜黑色素瘤诊疗水平  

Learning from the experience of collaborative research on ocular melanoma to improve the diagnosis and treatment level of uveal melanoma in China

作　　者：魏文斌[1] 周楠[1] Wei Wenbin;Zhou Nan(Beijing Tongren Eye Center,Beijing Tongren Hospital,Capital Medical University,Beijing Intraocular Tumor Key Laboratory,Beijing Ophthalmology&Visual Sciences Key Laboratory,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院、北京同仁眼科中心、眼内肿瘤诊治研究北京市重点实验室、北京市眼科学与视觉科学重点实验室,北京100730

出　　处：《中华眼底病杂志》2023年第10期803-809,共7页Chinese Journal of Ocular Fundus Diseases

摘　　要：在葡萄膜黑色素瘤(UM)的研究历程中,眼部黑色素瘤协作研究(COMS)是里程碑式的、卓越的临床研究。其研究结论是今天UM临床工作及指南制定的基础。COMS是首次也是迄今为止实施的最大的一组随机临床试验,比较两种或两种以上治疗方案对眼内原发恶性肿瘤的生存结果,可信度高;其研究设计、研究方法和研究结论,至今仍被广泛引用。学习COMS的研究经验,积极总结基于亚洲人群的研究数据,制定适合亚洲UM患者的治疗方法,既是对COMS数据的有力补充,也是对该项世界性研究的深入拓展,对进一步提高我国UM诊疗水平具有重要意义。In the research process of uveal melanoma(UM),the Collaborative Ocular Melanoma Study(COMS)is a landmark and outstanding clinical study.Its research conclusions are the foundation for today's UM clinical work and guidelines.COMS is the first and largest randomized clinical trials conducted to date,comparing the survival outcomes of two or more treatment regimens for primary malignant intraocular tumors with high reliability.Its research design,methods,and conclusions are still widely cited in this day.Learning from the research experience of COMS,summarizing research data based on Asian populations,and studying treatment methods suitable for Asian UM patients is a powerful supplement to COMS data,but also an expansion of this global research,further improving the level of UM diagnosis and treatment in China.

关 键 词：眼部黑色素瘤协作研究 葡萄膜黑色素瘤 经验总结 诊疗水平 述评 

分 类 号：R739.7[医药卫生—肿瘤]